679 related articles for article (PubMed ID: 25943321)
1. p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer.
Kim SH; Park KH; Shin SJ; Lee KY; Kim TI; Kim NK; Rha SY; Roh JK; Ahn JB
Cancer Res Treat; 2016 Jan; 48(1):208-15. PubMed ID: 25943321
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
[TBL] [Abstract][Full Text] [Related]
3. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
[TBL] [Abstract][Full Text] [Related]
4. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
Obermannová R; Van Cutsem E; Yoshino T; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; Garcia Alfonso P; Portnoy D; Cohn A; Yamazaki K; Clingan P; Lonardi S; Kim TW; Yang L; Nasroulah F; Tabernero J
Ann Oncol; 2016 Nov; 27(11):2082-2090. PubMed ID: 27573561
[TBL] [Abstract][Full Text] [Related]
5. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas.
Kim JC; Choi JS; Roh SA; Cho DH; Kim TW; Kim YS
Ann Surg Oncol; 2010 Jul; 17(7):1767-76. PubMed ID: 20077021
[TBL] [Abstract][Full Text] [Related]
6. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
Stintzing S; Miller-Phillips L; Modest DP; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
Eur J Cancer; 2017 Jul; 79():50-60. PubMed ID: 28463756
[TBL] [Abstract][Full Text] [Related]
7. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
8. CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer.
Kim SH; Park KH; Shin SJ; Lee KY; Kim TI; Kim NK; Rha SY; Ahn JB
Yonsei Med J; 2018 Jul; 59(5):588-594. PubMed ID: 29869456
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
10. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
11. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy.
Shen L; Catalano PJ; Benson AB; O'Dwyer P; Hamilton SR; Issa JP
Clin Cancer Res; 2007 Oct; 13(20):6093-8. PubMed ID: 17947473
[TBL] [Abstract][Full Text] [Related]
12. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
[TBL] [Abstract][Full Text] [Related]
13. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
[TBL] [Abstract][Full Text] [Related]
14. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
[TBL] [Abstract][Full Text] [Related]
15. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Michl M; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmueller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Mueller S; Lerch MM; Modest DP; Kirchner T; Jung A; Heinemann V;
Ann Oncol; 2016 Aug; 27(8):1565-72. PubMed ID: 27234640
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
17. Clinical and prognosis value of the CIMP status combined with MLH1 or p16
Saadallah-Kallel A; Abdelmaksoud-Dammak R; Triki M; Charfi S; Khabir A; Sallemi-Boudawara T; Mokdad-Gargouri R
Med Oncol; 2017 Aug; 34(8):147. PubMed ID: 28730335
[TBL] [Abstract][Full Text] [Related]
18. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
19. CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
Zhang X; Shimodaira H; Soeda H; Komine K; Takahashi H; Ouchi K; Inoue M; Takahashi M; Takahashi S; Ishioka C
Int J Clin Oncol; 2016 Dec; 21(6):1091-1101. PubMed ID: 27435270
[TBL] [Abstract][Full Text] [Related]
20. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Stintzing S; Modest DP; Rossius L; Lerch MM; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Giessen-Jung C; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
Lancet Oncol; 2016 Oct; 17(10):1426-1434. PubMed ID: 27575024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]